Stock Analysts’ upgrades for Tuesday, October 3rd:

Agnico Eagle Mines Limited (NYSE:AEM) (TSE:AEM) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. The firm currently has $51.00 target price on the stock. According to Zacks, “Earnings estimates for Agnico-Eagle for the third quarter have remained stable of late. The company has outperformed the industry it belongs to over the last six months. Agnico-Eagle maintains a solid exploration budget and is reinvesting in its assets to expand output. It is making a good progress with its key growth projects and is also expanding mine life across a number of properties. “

TD Ameritrade Holding Corporation (NASDAQ:AMTD) was upgraded by analysts at Zacks Investment Research from a hold rating to a strong-buy rating. The firm currently has $56.00 price target on the stock. According to Zacks, “Shares of TD Ameritrade have outperformed the industry in the past year. Yet, the company’s earnings surprise history is not that impressive. It surpassed the Zacks Consensus Estimate for earnings in only one of the trailing four quarters. We remain cautious of the elevated costs, which are likely to weigh on the financials. However, the company recorded a rise in average client trades per day in the fiscal third quarter with the trend continuing in the first two months of the current quarter. Further, its deal to acquire Scottrade is likely to be accretive to earnings per share (EPS) in double digits. Also, TD Ameritrade’s steady capital deployment activities and revenue growth are encouraging.”

Beacon Roofing Supply (NASDAQ:BECN) was upgraded by analysts at Zacks Investment Research from a strong sell rating to a hold rating. According to Zacks, “Beacon Roofing lowered revenue growth range for 2017 to 5-6% reflecting lower-than-expected sales rate in the third quarter. The company guides adjusted earnings per share between $2.15 and $2.25 for 2017. The commercial roofing market has been experiencing competitive pricing pressures recently. Year-over-year comparisons in the Southwest will remain difficult during the coming quarters and Eastern Canada will be impacted by competitive pressure; limited big project work and unfavorable weather. Beacon Roofing has underperformed the industry, year-to-date. However, Beacon Roofing's pending acquisition of Allied Building Products for $2.625 billion will catapult it to one of the largest public wholesale building materials distributors in North America. Beacon Roofing is also expected to benefit from the rebuilding activity triggered by the two back-to-back hurricanes Harvey and Irma.”

BlackRock (NYSE:BLK) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. Zacks Investment Research currently has $501.00 target price on the stock. According to Zacks, “BlackRock’s shares have underperformed the industry, in the last twelve months. Nevertheless, the company surpassed the Zacks Consensus Estimate for earnings in three of the trailing four quarters. The company is undertaking initiatives to restructure its actively managed equities business with an aim to meet changing client needs. These along with technological changes will further help top-line growth going forward. Also, it has expanded globally via acquisitions and remains well positioned to capitalize on opportunistic deals, given its strong liquidity position. However, mounting expenses mainly due to continued rise in marketing costs and high dependence on overseas revenues remain major concerns for the company.”

BP p.l.c. (NYSE:BP) was upgraded by analysts at Kepler Capital Markets from a reduce rating to a hold rating.

Conatus Pharmaceuticals (NASDAQ:CNAT) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Conatus presently has no approved product in its portfolio. The company’s lead candidate emricasan is in phase II development for treatment of chronic liver disease, including NASH fibrosis. We are positive on the company’s plans to initiate studies on emricasan, targeting different types of NASH patient populations as the market holds huge untapped potential. Though Conatus is progressing well with emricasan, it is still several years away from entering the market. Any development/regulatory setback on emricasan could hamper Conatus’ prospects. Notably, several companies are working on developing treatments for NASH which might make the market competitive for emricasan. The stock has underperformed the industry so far this year.”

Dominion Energy (NYSE:D) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. They currently have $86.00 target price on the stock. According to Zacks, “Dominion Energy is benefiting from its regulated growth projects and synergies from Questar acquisition are helping Dominion Energy. Dominion’s Greensville County Power Station and Cove Point Liquefaction project are proceeding on time and budget and are likely to boost the company’s performance over the long term. Contribution from Dominion Midstream will also boost results of the company. The company’s expansion of electric transmission, natural gas facilities and midstream assets are strong positives.However, lower solar investment tax credit, higher PJM electric capacity expenses and lower earnings from Cove Point due to the roll off of one of its import contracts may hurt the company's earnings in the near term.”

FMC Corporation (NYSE:FMC) was upgraded by analysts at Zacks Investment Research from a hold rating to a strong-buy rating. The firm currently has $103.00 price target on the stock. According to Zacks, “FMC Corp. has outperformed the industry it belongs to over a year. The company is seeing strong demand in its Lithium unit and is expanding production capacity to meet growing demand for electric vehicles. Moreover, FMC Corp. will benefit from the cost synergies of the Cheminova buyout. The proposed acquisition of a major portion of DuPont's Crop Protection business has also provided a significant growth platform for the company's Agricultural Solutions unit. The company should also gain from its efforts to expand product portfolio.”

Geron Corporation (NASDAQ:GERN) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. They currently have $2.50 target price on the stock. According to Zacks, “Geron is optimistic about the agreement with J&J for its lead pipeline candidate – imetelstat – which provides it a strong partner as well as funds. Imetelstat is being developed for the treatment of myelofibrosis and myelodysplastic syndromes. In 2016, J&J announced unfavorable findings from the planned internal reviews of initial data from the two studies of imetelstat, IMbark and IMerge. However, in April 2017, Geron informed that Janssen has completed the second internal data review of the two studies and as a result of the review, both trials are continuing unmodified. However, Geron's dependence on a single pipeline candidate, imetelstat, raises concerns. Moreover, Geron’s shares underperformed the industry so far this year.”

Harris Corporation (NYSE:HRS) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Shares of Harris Corporation have outperformed its industry so far this year. The company's efforts to reward shareholders through dividends and buybacks are impressive. In August, the company raised its quarterly dividend by 8% to 57 cents per share from 53 cents per share. This is the 16th such annual dividend increase by the company. The company has an impressive earnings history having surpassed the Zacks Consensus Estimate in three of the preceding four quarters. However, the company's revenue related woes are concerning. Moreover, the disappointing performance of its Space and Intelligence Systems unit may hurt the top line going forward. Harris is also a highly leveraged company. High integration and restructuring costs from acquisition are limiting bottom-line growth. Additionally, weakness in international markets may result in lower-than-expected sales of tactical radio products.”

Humana (NYSE:HUM) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. Zacks Investment Research currently has $273.00 price target on the stock. According to Zacks, “Humana is well poised to grow on its strong government business. Its top-line has been witnessing an uptrend from past many years. Sufficient generation of cash flow has helped the company take up several capital deployment initiatives aimed at enhancing shareholders’ value. Humana’s sound balance sheet and disciplined capital management remains a positive.  Following its strong second-quarter 2017 results, it raised its 2017 adjusted EPS guidance. The stock has also seen the Zacks Consensus Estimate for 2017 and 2018 earnings being revised upward in last 30 days. Although the shares have slighly underperformed the industry in past six months, its strong fundamentals are likely to help the stock in gaining momentum going forward.”

Methanex Corporation (NASDAQ:MEOH) (TSE:MX) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. The firm currently has $57.00 price target on the stock. According to Zacks, “Methanex has outperformed the industry it belongs to over a year. Methanex should gain from healthy demand fundamentals for methanol. We are also optimistic about its Louisiana project, which is expected to create significant value for shareholders and meaningfully contribute to cash generation. “

Anglo Amer Adr (OTCMKTS:NGLOY) was upgraded by analysts at HSBC Holdings plc from a hold rating to a buy rating.

Natixis SA (NASDAQ:NTXFY) was upgraded by analysts at Credit Suisse Group from a neutral rating to an outperform rating.

Orbital ATK (NYSE:OA) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. The firm currently has $150.00 target price on the stock. According to Zacks, “Shares of Orbital ATK have outperformed the industry in the last 12 months. Orbital ATK’s diverse product offering and its involvement in major development and production programs will continue to swell its order book. Orbital ATK’s ongoing R&D work will assist it to churn new products and further expand its defense and commercial market penetration. However, intense competition in the defense space, risk involved in operation, dependence on government budgets and fluctuations in currencies are potential growth deterrents.”

Pacira Pharmaceuticals (NASDAQ:PCRX) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. Zacks Investment Research currently has $42.00 price target on the stock. According to Zacks, “Pacira's efforts to expand Exparel's label to boost sales in oral surgery and chronic pain are encouraging. The company also remains optimistic of its partnership with J&J to market and promote the use of Exparel, with their sales and medical education teams. Going forwad, Pacira is looking to expand Exparel's label in the animal health market as well. Shares of the company have outperformed the industry year to date. However, Pacira’s dependence on its key marketed drug, Exparel, for top-line growth is concerning. The company also discontinued the production of DepoCyt(e) due to persistent technical issues specific to DepoCyt.”

Pfizer (NYSE:PFE) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. They currently have $40.00 target price on the stock. According to Zacks, “Pfizer is working on strengthening its product portfolio through acquisitions and licensing deals. However, Pfizer continues to face headwinds in the form of genericization of key drugs, lost alliance revenues, pricing pressure and rising competition which is hurting sales. Though Pfizer’s growing immuno-oncology portfolio offers strong potential, many of these assets are in early stage of development. Nonetheless, we believe that new products like Ibrance, contribution from acquisitions, cost-cutting efforts and share buybacks should help the company achieve its guidance. Pfizer also boasts a strong pipeline and expects approximately 25 to 30 drug approvals over the next five years, including around 15 products that have blockbuster potential. Bavencio is being considered a key long-term growth driver for Pfizer. The company has a mixed record of earnings surprises in recent quarters. Estimates have remained stable ahead of its Q3 results.”

Jean Coutu Group PJC (TSE:PJC.A) was upgraded by analysts at Barclays PLC from an underweight rating to an equal weight rating.

QUALCOMM (NASDAQ:QCOM) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Qualcomm continues to lead the global wireless baseband chipset market, along with its Snapdragon processors. Qualcomm is reportedly partnering with Himax Technologies’ to create a 3D camera module. The pending deal of NXP Semiconductor buyout is still under regulatory proceedings. Qualcomm has launched its Mesh Networking Platform. Qualcomm is planning to buy Scyfer B.V. to boost its Artificial Intelligence Research. Qualcomm’s subsidiary has unveiled a new chipset — the C-V2X (Cellular Vehicle-to-Everything), compatible with 4G and budding 5G cellular standards. However, the company continues to receive charges for unfair business practices and licensing royalty payments. Aggressive competition in the mobile phone chipset market has also been hurting Qualcomm’s profits. The $1 billion dispute with Apple is getting uglier. Over the past three months, the stock declined 5.6% as against the industry’s loss of 4.0%.”

Transocean (NYSE:RIG) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. The firm currently has $12.00 price target on the stock. According to Zacks, “Despite a difficult operating backdrop, Transocean has managed to beat estimates in each of the last 16 quarters. The offshore rig company's outperformance has been due to sustained cost cuts and impressive revenue efficiency. The recent bullish backdrop surrounding oil has further lifted the sentiment in the stock, which has rallied more than 8% in the past year, handily outperforming the Zacks Oil & Gas-Drilling industry's 15.7% decline. As it is, we are a fan of Transocean's technologically advanced and versatile drilling fleet , strong backlog and considerable pricing power. Finally, with a broad client base that includes most of the exploration and production biggies, we believe Transocean offers substantial upside potential from the current price levels.”

ResMed (NYSE:RMD) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “ResMed achieved strong global revenue growth over the past few quarters, led by sales of sleep devices, respiratory care devices, mask systems and software solutions. Also, Brightree has acted as a significant contributor to the company’s operating results through 2017. Notably, we believe, ResMed’s product launches and strategies to gain traction in the SDB market are expected to boost its performance further in the near term. Also, its recent published favorable study result on COPD buoys optimism. Over the last six months, ResMed has been observed to trade above the broader industry. However, we remain skeptical on certain fundamental factors that may weigh down the stock. In this regard, challenges like competitive bidding and reimbursement issues continue to plague the stock. Rising operating expenses and a weak operating margin are other major woes for ResMed.”

Sprint Corporation (NYSE:S) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. Zacks Investment Research currently has $8.50 target price on the stock. According to Zacks, “Sprint is on track with its network modernization and integration efforts, to fortify its position in the wireless industry. Sprint’s prepaid subsidiary has extended its unlimited offerings to its existing iPhone owners and has also inked deal with Apple to relaunch itself as an exclusive iPhone carrier. Sprint also offers attractive unlimited data plans to lure customers from rivals. We believe these efforts have driven the huge wireless subscribers. Sprint unveiled its Sprint MultiLine solution which allows businesses to add a company-owned number to their employees' personal phones for better businesses. For full-year 2017, Sprint has raised its outlook. Over the past three months, the stock price underperformed its industry. However, high cash burn from promotional offers and discounts, debt-laden balance sheet and decreasing cash flow have led to losses for Sprint. Further, Sprint operates in a highly competitive wireless market.”

Straumann Hldg (NASDAQ:SAUHY) was upgraded by analysts at Citigroup Inc. from a sell rating to a neutral rating.

Sucampo Pharmaceuticals (NASDAQ:SCMP) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Sucampo is focused on expanding Amitiza’s label and penetrating into new markets. Also, the company’s collaborations with firms like Takeda and Mylan for Amitiza’s commercialization is a big positive. Also, through the agreement with Cancer Prevention Pharmaceuticals, the company acquired an exclusive option to develop and commercialize its combination, CPP-1X/sulindac, in North America. Moreover, the Vtesse acquisition added a pivotal program in Niemann-Pick Disease type C1 to its pipeline. However, Sucampo’s dependence on Amitiza for growth is concerning. Also, some companies are trying to market and sell generic version of Amitiza. A decline in Amitiza's sales will adversely impact the top line. Moreover, it had its share of pipeline setbacks. The company has lowered its earnings outlook to include the Vtesee acquisition. Shares of the company have underperformed the industry.”

Standard Motor Products (NYSE:SMP) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Standard Motor is set to benefit from its solid brand recognition and regular capital deployment, which will enhance shareholder value. The company has been focused on reducing cost of production, which is expected to benefit its results. Standard Motor is not significantly exposed to the cyclical nature of the automotive industry since it is focused on the aftermarket, where it is a leading player. Moreover, Standard Motor’s shares have also underperformed the industry it belongs to, in the last six months.”

Square (NYSE:SQ) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. Zacks Investment Research currently has $32.00 target price on the stock. According to Zacks, “Square has outperformed the industry on a year-to-date basis. The company’s comprehensive commerce ecosystem, accelerated business growth and focus on integration, automation, and platform are key catalysts. The company's plan to open a wholly-owned brick-and-mortar bank is positive in our view. Meanwhile, automation is enabling the company to increase reach of financial system to more people, scale up its own operations and help sellers with advanced CRM tools. Moreover, the company displays consistent business growth through balancing investment and margin expansion. However, it’s currently a loss making enterprise, which doesn't augur with investors. Moreover, vulnerability to intense competition and changing technology, industry standards and seller and buyer needs pose signficant challenges.”

Unisys Corporation (NYSE:UIS) was upgraded by analysts at Zacks Investment Research from a strong sell rating to a hold rating. According to Zacks, “Unisys has significant pension obligations under its U.S. and non-U.S. defined benefit pension plans that are likely to be a drag on its earnings. In addition, Unisys has to continually invest in new technologies to provide a hedge against stiff competition, which increases operating expenses and reduces margins. Foreign currency volatility remains another concern for Unisys due to its significant international presence. The company also underperformed the industry year to date. However, Unisys is concentrating on business opportunities in fewer, more profitable markets in the IT marketplace and is revamping its sales strategy accordingly to improve its margins. The company is rationalizing its services and solution portfolio by shifting its offerings to cloud-based and software-as-a-service delivery models. Unisys is also focusing more to build specialized industry skills and resources required to win industry-specific project opportunities.”

Aqua America (NYSE:WTR) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. They currently have $38.00 price target on the stock. According to Zacks, “Aqua America already expanded its customer base through acquisitions during the first half of 2017. It aims to increase its customer level by 1.5-2% in 2017 through strategic acquisitions and organic initiatives. Rate hikes are boosting its earnings and the company is continuing with its infrastructural strengthening initiatives.The company aims to make capital investments of over $450 million in 2017, which is part of an ambitious investment target of more than $1.2 billion in the 2017-2019 period. However, Aqua America, like other water utilities runs the risk of contamination of water sources, which could raise its operating costs while fluctuating weather conditions might dampen demand for water.”

Watts Water Technologies (NYSE:WTS) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. The firm currently has $79.00 target price on the stock. According to Zacks, “Watts Water expects organic sales growth in the second half of 2017 to improve as compared with the first-half performance on the back of improved market conditions, product introductions and geographic expansion. In Americas, it anticipates consistent growth from relatively healthy end markets with AERCO. Watts Water continues to drive various transformation programs and investing in higher margin growth businesses. The company’s constant focus on productivity, acquisition strategy and cost savings actions also remain tailwinds. Watts Water's estimates have been undergoing positive revisions over the past two months. The company has a positive record of earnings surprises in recent quarters.”

Receive News & Ratings for Agnico Eagle Mines Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agnico Eagle Mines Limited and related companies with Analyst Ratings Network's FREE daily email newsletter.